HIGH-DOSE CISPLATIN AND BLEOMYCIN NEOADJUVANT CHEMOTHERAPY PLUS RADICAL SURGERY IN LOCALLY ADVANCED CERVICAL-CARCINOMA - A PRELIMINARY-REPORT

被引:57
作者
PANICI, PB [1 ]
GREGGI, S [1 ]
SCAMBIA, G [1 ]
RAGUSA, G [1 ]
BAIOCCHI, G [1 ]
BATTAGLIA, F [1 ]
CORONETTA, F [1 ]
MANCUSO, S [1 ]
机构
[1] UNIV CATTOLICA SACRO CUORE, DEPT GYNECOL & OBSTET, 8 LARGO AGOSTINO GEMELLI, I-00168 ROME, ITALY
关键词
D O I
10.1016/0090-8258(91)90310-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One course of chemotherapy containing cisplatin and bleomycin as a neoadjuvant treatment was given to 26 consecutive patients with previously untreated stage IB (bulky disease)-III cervical carcinoma and followed by radical surgery. After chemotherapy responses were detected in 23 patients (5 complete and 18 partial; overall, 88%) and permitted radical surgery in 21 cases (81%). Surgery consisted of type III-IV radical hysterectomy plus systematic para-aortic and pelvic lymphadenectomy. At histologic examination, complete responses were found in 5 (19%) and partial responses in 16 (62%) cases. The average number of lymph nodes removed was 61 (range, 38-118). A lower than expected incidence of lymph node metastases was detected ( 2 21, 9.5%). The chemotherapy-induced toxicity was mainly represented by nausea and vomiting. Chemotherapy did not seem to complicate surgery in these circumstances, even though moderate-degree postoperative complications occurred in 48% of cases. Eighteen months median follow-up time (range, 11-23) from hystological diagnosis has been reached in the operated patients, and no recurrences have been detected so far. © 1991.
引用
收藏
页码:212 / 216
页数:5
相关论文
共 38 条
[31]   RESULTS OF A PHASE-II TRIAL WITH NEOADJUVANT CHEMOTHERAPY IN CARCINOMA OF THE CERVIX UTERI [J].
SARDI, JE ;
DIPAOLA, GR ;
GIAROLI, A ;
SANANES, C ;
RUEDA, NG ;
CACHAU, A ;
VIGHI, S ;
BURLANDO, S .
GYNECOLOGIC ONCOLOGY, 1988, 31 (02) :256-261
[32]   THE PROGNOSTIC VALUE OF A RESPONSE TO CHEMOTHERAPY GIVEN BEFORE RADIOTHERAPY IN ADVANCED CANCER OF CERVIX [J].
SYMONDS, RP ;
BURNETT, RA ;
HABESHAW, T ;
KAYE, SB ;
SNEE, MP ;
WATSON, ER .
BRITISH JOURNAL OF CANCER, 1989, 59 (03) :473-475
[33]  
THIGPEN T, 1979, CANCER TREAT REP, V63, P1549
[34]  
THIGPEN T, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P116
[35]   HIGH-DOSE-RATE AFTERLOADING BRACHYTHERAPY IN CARCINOMA OF THE UTERINE CERVIX [J].
UTLEY, JF ;
VONESSEN, CF ;
HORN, RA ;
MOELLER, JH .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1984, 10 (12) :2259-2263
[36]   A PHASE-II TRIAL OF MITOMYCIN, VINCRISTINE, BLEOMYCIN, AND CISPLATIN (MOBP) AS NEOADJUVANT THERAPY IN HIGH-RISK CERVICAL-CARCINOMA [J].
WEINER, SA ;
ARISTIZABAL, S ;
ALBERTS, DS ;
SURWIT, EA ;
DEATHERAGEDEUSER, K .
GYNECOLOGIC ONCOLOGY, 1988, 30 (01) :1-6
[37]   PROTECTIVE EFFECT OF REDUCED GLUTATHIONE AGAINST CISPLATIN-INDUCED RENAL AND SYSTEMIC TOXICITY AND ITS INFLUENCE ON THE THERAPEUTIC ACTIVITY OF THE ANTITUMOR DRUG [J].
ZUNINO, F ;
PRATESI, G ;
MICHELONI, A ;
CAVALLETTI, E ;
SALA, F ;
TOFANETTI, O .
CHEMICO-BIOLOGICAL INTERACTIONS, 1989, 70 (1-2) :89-101
[38]  
1979, WHO OFFSET PUBLICATI, V48